Previous 10 | Next 10 |
Investment Thesis Alnylam 1-year share price performance. Source: TradingView Alnylam ( ALNY ) is arguably the best known and most advanced developer of RNAi therapeutics - using small interfering RNA ("siRNA") to identify messenger RNA ("mRNA") and disrupt the process by which it encode...
Patisiran Continues to Demonstrate Reversal of Neuropathy Progression, Improvement in Quality of Life, and Consistent Safety Profile with Additional 24 Months of Treatment in Global Open-Label Extension (OLE) Study Interim Data Presented on Patisiran Treatment in Patients with Disease ...
Alnylam Pharmaceuticals (NASDAQ: ALNY) has been a phenomenal biotech stock. The company had its initial public offering in 2004. Shares are now 22 times more valuable than they were 16 years ago. That's an incredible stock performance. And yet the company is still not profitable. ...
SAN FRANCISCO, May 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2...
Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...
Alnylam ’s ( ALNY ) management simply continues to execute, logging another quarter of better than expected results and moving the pipeline forward. While Covid-19 is going to create some near-term challenges for the Onpattro franchise, it should be recoverable later in the year provid...
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2020 Earnings Conference Call May 05, 2020, 10:00 AM ET Company Participants Christine Lindenboom - VP, IR and Corporate Communications John Maraganore - CEO Barry Greene - President Akshay Vaishnaw - President of R&D Jeff Poulton -...
Image source: The Motley Fool. Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Q1 2020 Earnings Call May 6, 2020 , 8:30 a.m. ET Operator Continue reading
Many of the companies included in this article are in the mix developing treatments for COVID-19, some already have possible therapies in place. But perhaps the thing they have in common the most is how their price charts are governed largely by investor sentiment. Most of these names sold off...
On Wednesday, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported first-quarter results that showed impressive sales growth for its recently launched drugs. Unfortunately, the COVID-19 pandemic has watered down the launch of its lead drug, Onpattro, and the company isn't quite as confident ...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...